Amarin files suit against AstraZeneca

Amarin Corp. plc has thrown up a legal flare against a drug candidate the company fears could lure away consumers from its fish-oil pill Vascepa.

Amarin, with R&D headquarters in Groton, filed suit this week against drug giant AstraZeneca, saying the company's experimental pill Epanova impinges on a patent. A few days earlier, Amarin had sued the U.S. Food and Drug Administration over changes in policy that have blocked wider use of Vascepa, a pill shown to lower blood-fat counts.

The FDA is expected to make a ruling on Epanova by May. AstraZeneca bought Epanova's developer Omthera last year for $323 million.


Loading comments...
Hide Comments